Taysha Gene Therapies, Inc. ( TSHA ) Reports Q2 Loss, Beats Revenue Estimates
Taysha Gene Therapies (TSHA) delivered earnings and revenue surprises of -28.57% and +15.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Commenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of No Objection Letter ( NOL ) from Health Canada and feedback from the FDA. patient enrollment anticipated to begin in ...
Amphastar Pharmaceuticals ( AMPH ) Q2 Earnings and Revenues Beat Estimates
Amphastar (AMPH) delivered earnings and revenue surprises of +19.72% and +2.69%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Will Taysha Gene Therapies, Inc. ( TSHA ) Report Negative Q2 Earnings? What You Should Know
Taysha Gene Therapies (TSHA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Taysha Gene Therapies ( NASDAQ:TSHA )
DALLAS, Aug. 01, 2025 ( GLOBE NEWSWIRE ) -- Taysha Gene Therapies, Inc.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
DALLAS, Aug. 01, 2025 ( GLOBE NEWSWIRE ) -- Taysha Gene Therapies, Inc. ( Nasdaq: TSHA ) ( Taysha or the Company ) , a clinical-stage biotechnology company focused on advancing adeno-associated virus ( AAV ) -based gene therapies for severe monogenic diseases of the central nervous system ( CNS ...
Taysha Gene Therapies ( TSHA ) Moves to Buy: Rationale Behind the Upgrade
Taysha Gene Therapies (TSHA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
DALLAS, July 03, 2025 ( GLOBE NEWSWIRE ) -- Taysha Gene Therapies, Inc. ( Nasdaq: TSHA ) ( Taysha or the Company ) , a clinical-stage biotechnology company focused on advancing adeno-associated virus ( AAV ) -based gene therapies for severe monogenic diseases of the central nervous system ( CNS ...
Personalis ( PSNL ) Surges 14.2%: Is This an Indication of Further Gains?
Personalis (PSNL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
DALLAS, June 06, 2025 ( GLOBE NEWSWIRE ) -- Taysha Gene Therapies, Inc. ( Nasdaq: TSHA ) ( Taysha or the Company ) , a clinical-stage biotechnology company focused on advancing adeno-associated virus ( AAV ) -based gene therapies for severe monogenic diseases of the central nervous system ( CNS ...
Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program
Recently disclosed clinical cohort data from high ( 1x1015 total vg ) and low dose ( 5.7x1014 total vg ) TSHA-102 from REVEAL adolescent/adult and pediatric Phase 1/2 trials ...
Why Is Taysha Gene Therapies Stock Trading Higher On Thursday? - Taysha Gene Therapies ( NASDAQ:TSHA )
100% of treated patients gained at least one developmental milestone after TSHA-102 across fine/gross motor and communication domains. No serious adverse events or dose-limiting toxicities were observed with TSHA-102 in the high- or low-dose cohorts.
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
DALLAS, May 28, 2025 ( GLOBE NEWSWIRE ) -- Taysha Gene Therapies, Inc. ( Nasdaq: TSHA ) ( Taysha or the Company ) , a clinical-stage biotechnology company focused on advancing adeno-associated virus ( AAV ) -based gene therapies for severe monogenic diseases of the central nervous system ( CNS ) ...
Taysha Gene Therapies, Inc. ( TSHA ) Reports Q1 Loss, Tops Revenue Estimates
Taysha Gene Therapies (TSHA) delivered earnings and revenue surprises of 0% and 9.62%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Assembly Biosciences ( ASMB ) Reports Q1 Loss, Tops Revenue Estimates
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 41.79% and 21.38%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation - Virtus LifeSci Biotech Clinical Trials ETF ( ARCA:BBC ) , Capricor Therapeutics ( NASDAQ:CAPR )
Virtus BBC ETF fell 9.74% to $17.15; SPDR XBI ETF dropped 6.63% to $77.17 on Tuesday. William Blair says Moderna faces increased scrutiny with mRNA vaccines under new CBER leadership. Get prepared for the Fed's next move-live with Matt Maley on Wednesday, May 7 at 6 PM ET. Reserve your free spot ...
Personalis ( PSNL ) Reports Q1 Loss, Tops Revenue Estimates
Personalis (PSNL) delivered earnings and revenue surprises of 21.74% and 18.20%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Will Taysha Gene Therapies, Inc. ( TSHA ) Report Negative Q1 Earnings? What You Should Know
Taysha Gene Therapies (TSHA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Assembly Biosciences ( ASMB ) Soars 24.0%: Is Further Upside Left in the Stock?
Assembly Biosciences (ASMB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
DALLAS, May 02, 2025 ( GLOBE NEWSWIRE ) -- Taysha Gene Therapies, Inc. ( Nasdaq: TSHA ) ( Taysha or the Company ) , a clinical-stage biotechnology company focused on advancing adeno-associated virus ( AAV ) -based gene therapies for severe monogenic diseases of the central nervous system ( CNS ) ...
AskBio Elects Dr. Laura Sepp-Lorenzino Independent Member of Board of Directors
Dr. Sepp-Lorenzino brings to AskBio over 30 years of executive, academic, and Board experience Other Board positions include Taysha Gene Therapies, Alliance for Regenerative Medicine ( ARM ) , and Thermo Fisher Scientific
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
DALLAS, April 04, 2025 ( GLOBE NEWSWIRE ) -- Taysha Gene Therapies, Inc. ( Nasdaq: TSHA ) ( Taysha or the Company ) , a clinical-stage biotechnology company focused on advancing adeno-associated virus ( AAV ) -based gene therapies for severe monogenic diseases of the central nervous system ( CNS ...
Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet - Corcept Therapeutics ( NASDAQ:CORT ) , Mr. Cooper Gr ( NASDAQ:COOP )
U.S. stocks traded mixed midway through trading, with the Dow Jones gaining more than 100 points on Monday. The Dow traded up 0.30% to 41,710.68 while the NASDAQ fell 1.29% to 17,099.00. The S&P 500 also fell, dropping, 0.41% to 5,557.99. Consumer staples shares jumped by 1.2% on Monday.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
DALLAS, March 07, 2025 ( GLOBE NEWSWIRE ) -- Taysha Gene Therapies, Inc. ( Nasdaq: TSHA ) ( "Taysha" or the "Company" ) , a clinical-stage biotechnology company focused on advancing adeno-associated virus ( AAV ) -based gene therapies for severe monogenic diseases of the central nervous system ( ...
Taysha Gene Therapies, Inc. ( TSHA ) Reports Q4 Loss, Tops Revenue Estimates
Taysha Gene Therapies (TSHA) delivered earnings and revenue surprises of 12.50% and 6.42%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
BridgeBio Pharma ( BBIO ) Reports Q4 Loss, Tops Revenue Estimates
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -20.18% and 10.98%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
DALLAS, Feb. 07, 2025 ( GLOBE NEWSWIRE ) -- Taysha Gene Therapies, Inc. ( Nasdaq: TSHA ) ( Taysha or the Company ) , a clinical-stage biotechnology company focused on advancing adeno-associated virus ( AAV ) -based gene therapies for severe monogenic diseases of the central nervous system ( CNS ...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Taysha Gene Therapies ( NASDAQ:TSHA )
DALLAS, Jan. 03, 2025 ( GLOBE NEWSWIRE ) -- Taysha Gene Therapies, Inc.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
DALLAS, Jan. 03, 2025 ( GLOBE NEWSWIRE ) -- Taysha Gene Therapies, Inc. ( Nasdaq: TSHA ) ( Taysha or the Company ) , a clinical-stage biotechnology company focused on advancing adeno-associated virus ( AAV ) -based gene therapies for severe monogenic diseases of the central nervous system ( CNS ...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
DALLAS, Dec. 06, 2024 ( GLOBE NEWSWIRE ) -- Taysha Gene Therapies, Inc. ( Nasdaq: TSHA ) ( Taysha or the Company ) , a clinical-stage biotechnology company focused on advancing adeno-associated virus ( AAV ) -based gene therapies for severe monogenic diseases of the central nervous system ( CNS ...
Hillenbrand Posts Better-Than-Expected Earnings, Joins Beazer Homes, Tapestry, Walt Disney And Other Big Stocks Moving Higher On Thursday - Huntington Ingalls Indus ( NYSE:HII )
U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Thursday. Shares of Hillenbrand, Inc. HI rose sharply in today's session following upbeat quarterly results. Hillenbrand reported quarterly earnings of $1.01 per share which beat the analyst consensus estimate of 92 ...
Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Advance Auto Parts ( NYSE:AAP )
U.S. stock futures were higher this morning, with the Dow futures gaining more than 50 points on Thursday. Shares of Advance Auto Parts, Inc. AAP fell sharply in today's pre-market trading after the company reported downbeat quarterly results.
Why DLocal Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - DLocal ( NASDAQ:DLO )
Shares of DLocal Limited DLO rose sharply in today's pre-market trading after the company reported better-than-expected third-quarter revenue results. DLocal reported quarterly earnings of 9 cents per share which missed the analyst consensus estimate of 11 cents per share.
Taysha Gene Therapies, Inc. ( TSHA ) Reports Q3 Loss, Lags Revenue Estimates
Taysha Gene Therapies (TSHA) delivered earnings and revenue surprises of -12.50% and 4.54%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Dow Dips Over 200 Points; Home Depot Posts Upbeat Earnings - Pagaya Techs ( NASDAQ:PGY )
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 200 points on Tuesday. The Dow traded down 0.54% to 44,053.04 while the NASDAQ fell 0.01% to 19,299.60. The S&P 500 also fell, dropping, 0.09% to 5,995.74. Communication services shares surged by 0.5% ...
Tyson Foods Posts Better-Than-Expected Earnings, Joins Shopify, Sea, Buckle And Other Big Stocks Moving Higher On Tuesday - Tyson Foods ( NYSE:TSN )
U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday. Shares of Tyson Foods, Inc. TSN rose sharply during Monday's session following upbeat quarterly earnings. The company reported fourth-quarter adjusted earnings per share of 92 cents beating the street view ...
BridgeBio Pharma ( BBIO ) Reports Q3 Loss, Lags Revenue Estimates
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of 16.50% and 54.21%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Why Grab Holdings Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Grab Holdings ( NASDAQ:GRAB )
Shares of Grab Holdings Limited GRAB rose sharply in today's pre-market trading after the company posted better-than-expected results for its third quarter and raised its 2024 outlook. The company reported quarterly earnings of 1 cent per share, compared to consensus estimates of a loss of 1 cent ...
Personalis ( PSNL ) Reports Q3 Loss, Tops Revenue Estimates
Personalis (PSNL) delivered earnings and revenue surprises of -93.94% and 24.40%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
DALLAS, Nov. 01, 2024 ( GLOBE NEWSWIRE ) -- Taysha Gene Therapies, Inc. ( Nasdaq: TSHA ) ( Taysha or the Company ) , a clinical-stage biotechnology company focused on advancing adeno-associated virus ( AAV ) -based gene therapies for severe monogenic diseases of the central nervous system ( CNS ...
Taysha Gene Therapies ( TSHA ) Upgraded to Strong Buy: Here's Why
Taysha Gene Therapies (TSHA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Taysha Gene Therapies ( NASDAQ:TSHA )
DALLAS, Oct. 04, 2024 ( GLOBE NEWSWIRE ) -- Taysha Gene Therapies, Inc.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
DALLAS, Oct. 04, 2024 ( GLOBE NEWSWIRE ) -- Taysha Gene Therapies, Inc. ( Nasdaq: TSHA ) , a clinical-stage biotechnology company focused on advancing adeno-associated virus ( AAV ) -based gene therapies for severe monogenic diseases of the central nervous system ( CNS ) , today announced that, ...
Bausch ( BHC ) Surges 11.7%: Is This an Indication of Further Gains?
Bausch (BHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Taysha Gene Therapies ( NASDAQ:TSHA )
DALLAS, Sept. 06, 2024 ( GLOBE NEWSWIRE ) -- Taysha Gene Therapies, Inc.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
DALLAS, Sept. 06, 2024 ( GLOBE NEWSWIRE ) -- Taysha Gene Therapies, Inc. ( Nasdaq: TSHA ) , a clinical-stage biotechnology company focused on advancing adeno-associated virus ( AAV ) -based gene therapies for severe monogenic diseases of the central nervous system ( CNS ) , today announced that, ...
Taysha Gene Therapies, Inc. ( TSHA ) Reports Q2 Loss, Lags Revenue Estimates
Taysha Gene Therapies (TSHA) delivered earnings and revenue surprises of 10% and 69.28%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Presented cohort one ( low dose ) data from both trials of TSHA-102 at 2024 IRSF Rett Syndrome Scientific Meeting that demonstrated durable improvements across consistent clinical domains and an encouraging safety profile in adult ( up to 52 weeks ) and pediatric ( up to 22 weeks ) patients ...
Inotiv, Inc. ( NOTV ) Reports Q3 Loss, Lags Revenue Estimates
Inotiv (NOTV) delivered earnings and revenue surprises of -122.22% and 14.51%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Personalis ( PSNL ) Reports Q2 Loss, Tops Revenue Estimates
Personalis (PSNL) delivered earnings and revenue surprises of 29.41% and 14.01%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
